Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Moderna, Inc. - Common Stock (NQ:MRNA)

64.66 +1.34 (+2.11%)
Streaming Delayed Price Updated: 11:22 AM EDT, Aug 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Moderna, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
Moderna (MRNA): Buy, Sell, or Hold Post Q2 Earnings?
What a fantastic six months it’s been for Moderna. Shares of the company have skyrocketed 44.2%, hitting $63.36. This was partly due to its solid quarterly r... 
Via StockStory
News headline image
3 Unprofitable Stocks We Keep Off Our Radar
Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to conv... 
Via StockStory
Get insights into the top movers in the S&P500 index of Monday's pre-market session. ↗
Via Chartmill
News headline image
Moderna (MRNA) Q2 2026 Earnings Call Transcript ↗
Net loss improved 5% on international partnerships and manufacturing gains. 
Via The Motley Fool
Topics Earnings
Stay informed with the top movers within the S&P500 index on Friday. ↗
Via Chartmill
Top S&P500 movers in Friday's session ↗
Via Chartmill
What's going on in today's pre-market session: S&P500 movers ↗
Via Chartmill
News headline image
Moderna Receives U.S. FDA Approval for Influenza Vaccine mFLUSIVA
From Moderna, Inc.
Via ACCESS Newswire
News headline image
Prediction: These 2 Stocks Will Keep Winning No Matter What the Market Does ↗
These innovative biotech companies should reap the benefits of their breakthroughs. 
Via The Motley Fool
News headline image
MRNA Q2 Deep Dive: Pipeline Progress and Seasonal Vaccine Dynamics Shape Outlook
Biotechnology company Moderna (NASDAQ:MRNA) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 2.1% year on year to $145 mi... 
Via StockStory
News headline image
Moderna Announces Initiation of Phase 1 Clinical Trial of mRNA-1469, Moderna's Investigational Vaccine Against Bundibugyo Ebolavirus
From Moderna, Inc.
Via ACCESS Newswire
News headline image
Moderna Q2 Earnings Call Highlights ↗
Moderna (NASDAQ:MRNA) reported second-quarter revenue of $145 million, exceeding the high end of its prior guidance range, while continuing to reduce costs and advance programs spanning respiratory... 
Via MarketBeat
Topics Earnings
Get insights into the top movers in the S&P500 index of Friday's pre-market session. ↗
Via Chartmill
News headline image
Moderna (NASDAQ:MRNA) Beats Expectations in Q2 CY2026
Biotechnology company Moderna (NASDAQ:MRNA) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 2.1% year on year to $145 m... 
Via StockStory
News headline image
Moderna Reports Second Quarter 2026 Financial Results and Provides Business Updates
From Moderna, Inc.
Via ACCESS Newswire
News headline image
Moderna (MRNA) Q2 Earnings: What To Expect
Biotechnology company Moderna (NASDAQ:MRNA) will be announcing earnings results this Friday before market hours. Here’s what investors should know. Moderna b... 
Via StockStory
Topics Artificial Intelligence
News headline image
1 Healthcare Stock to Keep an Eye On and 2 We Avoid
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have not only reali... 
Via StockStory
News headline image
After Soaring Nearly 90% Thus Far in 2026, Is Moderna's Stock Still a Buy? ↗
Moderna's stock recently hit a new 52-week high after receiving positive news surrounding one of its vaccines. 
Via The Motley Fool
News headline image
Q1 Earnings Highlights: Moderna (NASDAQ:MRNA) Vs The Rest Of The Therapeutics Stocks
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q1. Today, we are looking a... 
Via StockStory
Topics Artificial Intelligence
News headline image
Moderna: A Stock to Watch or a Risky Bet? ↗
Could Moderna be the next big opportunity in biotech? Join our experts as they dissect the company's strengths and weaknesses, revealing insights that could shape your investment strategy. 
Via The Motley Fool
News headline image
Therapeutics Stocks Q1 Highlights: Moderna (NASDAQ:MRNA)
Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at Moderna (NASDAQ:MRNA) and its... 
Via StockStory
Topics Artificial Intelligence
News headline image
Therapeutics Stocks Q1 Teardown: Amgen (NASDAQ:AMGN) Vs The Rest
Looking back on therapeutics stocks’ Q1 earnings, we examine this quarter’s best and worst performers, including Amgen (NASDAQ:AMGN) and its peers. Over the ... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Should You Buy Moderna Stock Hand Over Fist Before Aug. 5? ↗
The biotech has been on a tear lately. 
Via The Motley Fool
News headline image
Moderna Is Up 109% in 2026. Jim Cramer Just Called It 'Finally Investable Again.' Is the Stock a No-Brainer Buy on Its Recent Pullback? ↗
A fresh era of earnings growth may be on the horizon. 
Via The Motley Fool
News headline image
Moderna (MRNA): Buy, Sell, or Hold Post Q1 Earnings?
The past six months have been a windfall for Moderna’s shareholders. The company’s stock price has jumped 46.4%, hitting $62.97 per share. This was partly th... 
Via StockStory
Exploring the top movers within the S&P500 index during today's session. ↗
Via Chartmill
News headline image
Moderna Announces First Participant Dosed in Phase 1 Clinical Trial Evaluating Investigational Tumor-Targeted Cancer Antigen Therapy in Solid Tumors
From Moderna, Inc.
Via ACCESS Newswire
News headline image
Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks
Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at Natera (NASDAQ:NTRA) and its ... 
Via StockStory
Topics Artificial Intelligence
News headline image
Spotting Winners: Gilead Sciences (NASDAQ:GILD) And Therapeutics Stocks In Q1
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ... 
Via StockStory
Topics Artificial Intelligence
News headline image
Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks
The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how biotechnology stocks f... 
Via StockStory
Topics Artificial Intelligence
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.